DOP2015000070A - Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide - Google Patents

Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide

Info

Publication number
DOP2015000070A
DOP2015000070A DO2015000070A DO2015000070A DOP2015000070A DO P2015000070 A DOP2015000070 A DO P2015000070A DO 2015000070 A DO2015000070 A DO 2015000070A DO 2015000070 A DO2015000070 A DO 2015000070A DO P2015000070 A DOP2015000070 A DO P2015000070A
Authority
DO
Dominican Republic
Prior art keywords
treat
procedures
useful drugs
reumatoid arthritis
manufacturing useful
Prior art date
Application number
DO2015000070A
Other languages
English (en)
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of DOP2015000070A publication Critical patent/DOP2015000070A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos anti-GM-CSF para utilizarse en el tratamiento de artritis reumatoide. Los anticuerpos anti-GM-CSF, en particular MOR103, se administran a los pacientes que padezcan de artritis reumatoide en cantidades que sean benéficas en una situación clínica.
DO2015000070A 2012-09-20 2015-03-20 Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide DOP2015000070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
DOP2015000070A true DOP2015000070A (es) 2015-08-16

Family

ID=46963526

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000070A DOP2015000070A (es) 2012-09-20 2015-03-20 Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide

Country Status (22)

Country Link
US (4) US20150246969A1 (es)
EP (3) EP3916013A1 (es)
JP (4) JP2015533806A (es)
KR (4) KR20230041086A (es)
CN (2) CN104995210A (es)
AU (2) AU2013320261A1 (es)
BR (1) BR112015006189B1 (es)
CL (2) CL2015000696A1 (es)
CR (1) CR20150153A (es)
DO (1) DOP2015000070A (es)
EA (1) EA031489B1 (es)
HK (1) HK1208231A1 (es)
IL (1) IL237554B (es)
IN (1) IN2015KN00657A (es)
MA (1) MA37946B1 (es)
MX (2) MX382937B (es)
MY (1) MY175388A (es)
PE (1) PE20151079A1 (es)
PH (1) PH12015500591A1 (es)
SG (2) SG10201803778PA (es)
UA (1) UA117228C2 (es)
WO (1) WO2014044768A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3916013A1 (en) * 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
AR100268A1 (es) * 2014-05-07 2016-09-21 Takeda Gmbh Formulación líquida que comprende compuesto neutralizante de gm-csf
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AU2017248264B2 (en) 2016-04-07 2020-01-30 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
PL3328887T3 (pl) 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Przeciwciała anty-gm-csf i ich zastosowania
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP2001501619A (ja) 1996-10-04 2001-02-06 アムジェン インコーポレーテッド ｍｐｌリガンドを含有する医薬組成物
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
US20100209434A1 (en) * 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
AR065910A1 (es) * 2007-04-02 2009-07-08 Genentech Inc Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b
WO2008122415A1 (en) 2007-04-05 2008-10-16 Sandoz Ag Stable aqueous g-csf formulations
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
MX2010005291A (es) 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
ES2978209T3 (es) * 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
EP2427495A1 (en) * 2009-05-05 2012-03-14 MorphoSys AG Treatment for multiple sclerosis
RS53010B (sr) 2009-12-31 2014-04-30 Arven Ilac Sanayi Ve Ticaret A.S. Novi postupak za pripremu g-csf (faktora stimulacije kolonije granulocita)
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
CN103827143A (zh) 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
EP3916013A1 (en) * 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody

Also Published As

Publication number Publication date
PH12015500591B1 (en) 2015-05-11
MX2015003644A (es) 2015-09-25
UA117228C2 (uk) 2018-07-10
MX382937B (es) 2025-03-13
KR20220028177A (ko) 2022-03-08
AU2016250388B2 (en) 2018-07-19
CL2015000696A1 (es) 2015-10-23
US20210130451A1 (en) 2021-05-06
CL2018000933A1 (es) 2018-07-20
MA37946A1 (fr) 2018-01-31
US20150246969A1 (en) 2015-09-03
MA37946B1 (fr) 2018-09-28
JP2018138551A (ja) 2018-09-06
EP2897977A1 (en) 2015-07-29
IL237554A0 (en) 2015-04-30
AU2016250388A1 (en) 2016-11-17
US20180230208A1 (en) 2018-08-16
HK1208231A1 (en) 2016-02-26
US10913792B2 (en) 2021-02-09
IN2015KN00657A (es) 2015-07-17
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
CA2884124A1 (en) 2014-03-27
SG10201803778PA (en) 2018-06-28
CN109999195A (zh) 2019-07-12
KR20240091288A (ko) 2024-06-21
JP2022169709A (ja) 2022-11-09
BR112015006189A2 (pt) 2019-11-26
IL237554B (en) 2019-12-31
KR20150056846A (ko) 2015-05-27
BR112015006189B1 (pt) 2022-04-05
EP3345923A1 (en) 2018-07-11
CN104995210A (zh) 2015-10-21
EA201590359A1 (ru) 2015-08-31
PH12015500591A1 (en) 2015-05-11
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
JP2024156992A (ja) 2024-11-06
MX2021006111A (es) 2021-07-07
EA031489B1 (ru) 2019-01-31
US20240417455A1 (en) 2024-12-19
EP3916013A1 (en) 2021-12-01
CR20150153A (es) 2015-09-14
JP2015533806A (ja) 2015-11-26
PE20151079A1 (es) 2015-08-07
AU2013320261A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
MX2015003644A (es) Tratamiento para artritis reumatoide.
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
EA201991484A1 (ru) Лекарственные формы энзалутамида
UY35490A (es) Conjugados de fármacos con anticuerpos
EA201591166A1 (ru) Ингибиторы аутотаксина
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
EA201391106A1 (ru) Новые гетероциклические производные
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
IL233313A0 (en) Composition of novel carbohydrate drug for treatment of human diseases
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
BR112013023187A2 (pt) regimes de dosagem para o tratamento da doença de fabry
UA112448C2 (uk) Композиція і спосіб лікування аутоімунного захворювання
CN302570696S (zh) 医用注射器
CN302570694S (zh) 医用注射器
CN302570695S (zh) 医用注射器
CN302470056S (zh) 医用注射器
CN302470057S (zh) 医用注射器